First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A new antipsychotic drug to treat symptoms of psychosis associated with Parkinson’s disease like hallucinations and delusions has become the first to be approved by the FDA.

The drug, called Nuplazid (pimavanserin), is the first of its kind on the market for use by people living with Parkinson’s in the US. It works only on the serotonin system, meaning – unlike previous antipsychotic medication – it doesn’t worsen motor symptoms.

It is estimated that around half the people with the condition may at some point experience hallucinations (seeing things that aren’t there) or delusions (holding false, paranoid, beliefs), also referred to as psychosis.

Dr Mitchell Mathis, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said: “Nuplazid represents an important treatment for people with Parkinson’s.”

Nuplazid is developed by Acadia Pharmaceuticals and will be available from June 2016 at the estimated annual cost of US$23,400.

Go Back

Share this story

Comments


Related articles


A woman ties her shoelaces, with a smartphone on the floor beside her.

Resources & Tools

Five more apps for people with Parkinson’s

Access Parkinson’s disease support on your smartphone

READ MORE

Perspectives

From New York to Toronto: the 500-mile walk that raised $750,000 for Parkinson’s research

500 miles, $750,000 and an unexpected visit from an old friend

READ MORE
Bike

Interviews

Pedalling for Parkinson’s

We talk to the founder of The Bike Box Project in New Bern, North Carolina

READ MORE